29 Marijuana Stocks to Buy as the Future Turns Green. Peak Pharmaceuticals, Inc., formerly known as Cannabis Therapy Corp, is based in Aurora, Colorado. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. The company's Stock price change every day as a result of market forces. If more people want to buy a stock (demand) than sell it (supply), then the price moves up. Zacks Investment Research is releasing its prediction for PKPH based on the month trading system that nearly. PKPH: Cannabis Therapy Corp. - Full Company Report. Get the latest Full Company Report for Cannabis Therapy Corp. from Zacks Investment Research.
Corp. ) Therapy Cannabis (PKPH
The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations.
The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein.
In no event shall GuruFocus. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
FilingWiz Note User Manual. Get 7-Day Free Trial. Click here to check it out. Only PremiumPlus Member can access this feature. Please enter Portfolio Name for new portfolio. It is based on these factors: A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit. Profitability Rank is not directly related to the Financial Strength Rank.
Analyzing the industry as a whole and looking back at the first year in history where marijuana has been legal, we can really study what the good investments were and what trades were not so profitable. With such a burgeoning space there is way more "noise" that can affect the success of companies involved within this space. These include local business chambers of commerce, political opposition, and federal regulation, but one aspect that flies under the radar, so to speak, has been involvement within biotech and pharmaceuticals.
Furthermore, hemp's legal status has made it an attractive target for companies looking to steer clear of the conflicting U. This is a British based biopharmaceutical company, which has become well-known for its novel approach to pharmaceutical therapy. The company's multiple sclerosis treatment product, Sativex, nabiximols is the first natural cannabis plant derivative to gain full market approval in any country. Over the last 18 months during the "dawn of marijuana legalization", this was one of the stocks to watch.
R in the field of severe, drug-resistant childhood epilepsy sparked a strong surge in momentum. The update was made in conjunction with the company's announcement on the results from its first of three Phase 3 trials for the investigational product Sativex in "the treatment of pain in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy".
This is a price that GWPH shares have not seen since late November and marked the first time that the stock showed signs of reversing from the previous downtrend just prior to the close of Furthermore, GWPH could be looking at a bull-flag pattern, setting up for a possible break to higher levels.
As you'll see with these additional cannabis biotechs, the entire sector seems to be lifting right now. This is significantly higher from prior years and a potential point of risk for GW. Being that the company is very dependent on its single product, Sativex, investors should be aware that though this is a larger market cap company in the cannabis space, there are regulatory approvals that will still need to be met by the FDA in the US.
For this company, Insys focuses on a sublingual spray as a delivery method and is moving forward with research and trials for pharmaceutical cannabinoids both for pain therapy in cancer patients as well as treatment for pediatric epilepsy. The company has already submitted an Investigational New Drug application for the pharmaceutical cannabidiol formulation for the treatment of epilepsy. In a recent press release, the company focused on development in citing that it will be conducting Phase III studies for its buprenorphine sublingual spray for the treatment of acute pain and expects to complete this by This mix of positive news, new studies in the pipeline and positive results from its most recent quarterly filing have helped to propel the stock to new highs and continue the latest bull-run.
The results include a Furthermore, the company operates fairly lean. In line with this, the share price has remained on an upward trend since May of last year. As hemp gains more popularity for a source of CBDs, its legal status has made it a very appealing target for companies looking to avoid the U.
For instance, in , the U. Supreme Court ruled in HIA v. DEA that hemp would be legal to cultivate and process for sale "as a food or beverage in the United States". The bill titled "Industrial Hemp Farming Act of " would "remove federal restrictions on the domestic cultivation of industrial hemp. The reason for this is because up until recently, companies manufacturing hemp-based products were forced to import the raw material.
Aside from GW Pharma and Insys, other companies are also coming on board and adopting a more biotechnology focused approach to the market opportunity in this burgeoning cannabis space. CTCO , which has received increased market attention following its name change and recent focus on the animal markets. Recently the company signed a worldwide license agreement with Canna-Pet LLC and a cultivation agreement with a Colorado-based hemp farm.
This should bode well for PEAK not only for opportunity for growth in the medical cannabis space but also in the pet markets as well. Thursday the company announced favorable sales results for its Canna-Pet product. According to PEAK, the company has processed and shipped more than 3, orders. According to the company, this increase in net cash used in operations was primarily due to the change in operating plans.
PA through its subsidiary, Oxis Biotech, Inc. It appears that following the company becoming current with its filings as well as releasing two very prominent pieces of press, activity in the stock has increased with January 14 seeing the highest volume day in the stock. This was an obvious trigger to take a closer look as seemingly, "something's up".
Over recent weeks, the company has made two announcements that put this on the list of possible cannabis investments in and both are material in nature. Further diligence shows that not only has Oxis executed definitive agreements licensing certain assets for the treatment of multiple myeloma but the company has also brought on one of the foremost authorities in CBD research especially those diagnosed with multiple myeloma, breast cancer, and even research in the stem cell arena, Dr.
According to the website cbdligand. The methods and results developed will have a significant impact on the other GPCRs drug research in general. Currently, he has established collaboration with MD experts in University of Pittsburgh Medical Center for in vivo animal evaluation.
Among many of his accomplishments, Dr. Under the helm of Mr. As far as paid in capital is concerned, Oxis shows more of a vested interest along the lines of a company like Insys as opposed to one like PEAK. Therefore it could be very possible that the CEO who took Genesis to "the next level" may have found another company to build as OXIS has continued to gain more investor interest this past week.
Despite these achievements and increased market liquidity, the obvious risks unassociated with the small market cap, lower share price, and volatility will also include the fact that Oxis will still need to put in place a plan or outline for what the company will focus on specifically.
This valuation method has been used because when you're not selling product, how can success be determined? By utilizing "paid-in-capital" valuations, investors can clearly see that amount of capital available to fund a biotech company's research. Investing in cannabis companies in the US at this point remains highly speculative and obvious risks reach far beyond simple market volatility.
Peak Pharmaceuticals Inc. ehemals Cannabis Therapy Corp. $CTCO
PKPH: Cannabis Therapy Corp. Greek Montage stock information. Get the latest Greek Montage stock quote information from Zacks Investment Research. Latest Breaking news and Headlines on Peak Pharmaceuticals, Inc. (PKPH) stock from Seeking Alpha. Cannabis Therapy licenses animal health products. BOULDER, CO--(Marketwired - Jan 13, ) - Peak Pharmaceuticals, Inc. ( OTCQB: CTCO), formerly Cannabis Therapy Corp.